BRAF inhibition is also associated with complications of cutaneous squamous cell carcinomas, which is an on-target adverse effect resulting from the paradoxical activation of the MAPK pathway in cells with wild type BRAF and strong upstream signaling in the MAPK pathway and is of particular relevance when combined with immunotherapies [23]. This evidence concerns the gene BRAF and squamous cell carcinoma.